A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / email@example.com
This is a research study to determine how safe and effective a new treatment, called IMC-F106C, is for treating advanced cancers. This study is the first time the study drug is being tested in people. IMC-F106C has been developed to treat cancer by activating the body's own immune system to fight the tumor. The study drug has 2 parts. The first part, called a T cell receptor, sticks very tightly to tumor cells that make markers called HLA-A*02:01 and PRAME. The second part, called anti-CD3 scFv, sticks to a T cell (a type of white blood cell that helps protect your body against disease). IMC F106C makes the T cell stick to the cancer cell, which then sends a signal to attack the tumor. Cancers include: Bladder cancer, breast cancer, gynecologic cancer, ovarian cancer, uterine (endometrial) cancer, kidney cancer/adrenal cancer, lung cancer, skin cancer, and melanoma.
Benjamin Izar, MD
|Are you at least 18 years of age?
|Are you able to perform every day tasks independently?
|Have you been diagnosed with advanced cancer?